Latest Breaking News On - Revumenib syndx 5613 - Page 1 : comparemela.com

Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia.

Zuid hollandUnited statesC michel zwaanSyndax pharmaceuticalsAmerican society of pediatric hematology oncologyPhase 2 augment 101 study2024 american society of pediatric hematology oncologyKmt2a rearranged acute leukemiaRevumenib syndx 5613